XXXX : a histologic subtype with poor prognosis.

@entity1 @entity902 @entity146 @entity5 @entity957 @entity2 @entity3 @entity1962 @entity420
INTRODUCTION: The aim of this study is to evaluate the prognostic factors and outcome of @entity1 operated for @entity1962 ( @entity1962 ) @entity2 , in comparison with @entity420 ( @entity420 ) and @entity957 ( @entity957 ). METHODS: a retrospective review of our thoracic @entity5 surgical database for @entity1 operated for @entity1962 , @entity957 and @entity420 between January, 1995 and December, 2009 was done. RESULTS: Forty-eight @entity1 (39 males, 81.3%) had @entity1962 ; complete @entity5 resection and lymphadenectomy was accomplished in all @entity1 . A higher stage at presentation was observed in @entity1962 , as compared to @entity420 or @entity957 (p=0.0001). Three and 5-year survival rates were 25% and 15%. @entity1962 overall survival was worse than @entity420 or @entity957 (p=0.0005). Three and 5-year survival rates of @entity1962 Stage I were similar to those of Stage IIIA @entity420 or @entity957 . More than half @entity1962 @entity1 developed distant @entity3 ( @entity3 ) or local recurrences. Brain @entity3 were the most frequent. Median survival for those @entity1 was 8  2.3 months. Postoperative @entity902 -based chemotherapy statistically improved @entity1 survival (p=0.02). In the multivariate analysis, the presence of @entity3 (p=0.001), the @entity5 perineural invasion (p=0.01) and the @entity5 stage (p=0.0005) were factors associated with poor prognosis. Adjuvant chemotherapy was a significant positive prognostic factor (p=0.00001). CONCLUSIONS: @entity1962 are uncommon and @entity146 . Adjuvant chemotherapy should be administered even in Stage I radically resected @entity5 . A whole brain postoperative prophylactic radiotherapy could be proposed to reduce risk of developing brain @entity3 .
